News

Geron Corp. quits stem cell work

The Menlo Park-based biotechnology firm Geron Corp. announced recently that it was abandoning its stem cell research in favor of focusing on two cancer drugs.

The motivation appears financial, according to a statement issued by the company.

"The decision to narrow Geron's technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities," the company said.

As a result, 66 jobs -- 38 percent of its workforce -- will be eliminated, the company said.

The news came as a blow to those hoping to benefit from stem cell therapy, a field that held promise for those paralyzed by spinal cord injuries.

Stem cells possess the ability to become any other type of cell in the body, leading Geron's scientists to explore how to grow the cells into replacement neurons that could reverse paralysis.

Comments

There are no comments yet. Please share yours below.

Post a comment

Posting an item on Town Square is simple and requires no registration. Just complete this form and hit "submit" and your topic will appear online. Please be respectful and truthful in your postings so Town Square will continue to be a thoughtful gathering place for sharing community information and opinion. All postings are subject to our TERMS OF USE, and may be deleted if deemed inappropriate by our staff.

We prefer that you use your real name, but you may use any "member" name you wish.

Name: *

Select your neighborhood or school community: * Not sure?

Choose a category: *

Since this is the first comment on this story a new topic will also be started in Town Square! Please choose a category that best describes this story.

Comment: *

Verification code: *
Enter the verification code exactly as shown, using capital and lowercase letters, in the multi-colored box.

*Required Fields

Flirtation
By Chandrama Anderson | 4 comments | 1,547 views

King of the Slides
By Cheryl Bac | 3 comments | 1,184 views

Standardized Test Prep: When to Start and Whom to Hire?
By John Raftrey and Lori McCormick | 0 comments | 728 views

Where the Sidewalk Ends
By Paul Bendix | 1 comment | 371 views